Inflammatory Bowel Diseases
Conditions
Brief summary
Navigating the risk-benefit profiles of the various biologic options approved for inflammatory bowel disease (IBD) can be challenging for patients who are considering biologic therapies as a treatment option. Thus, there is a need for simple and efficient tools that elicit individual preferences and support the patient-provider interaction. The principal objective of this study is to assess the impact of an online decision aid called IBD&me on patient perceptions of shared-decision making as compared to a standardized education arm.
Detailed description
Context: Navigating the risk-benefit profiles of the various biologic options approved for inflammatory bowel disease (IBD) can be challenging for patients who are considering biologic therapies as a treatment option. Thus, there is a need for simple and efficient tools that elicit individual preferences and support the patient-provider interaction. Objective: The principal objective of this study is to assess the impact of an online decision aid called IBD&me on patient perceptions of shared-decision making as compared to a standardized education arm. Hypothesis: IBD&me, through optimizing shared-decision making (SDM) and improving the patient-provider interaction, will provide incremental benefits beyond those provided by high-quality educational material without an SDM tool. Design: Pragmatic multicenter randomized controlled trial in IBD outpatient care 1. Intervention: IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace 2. Control arm: Standardized, high-quality educational material from the Crohn's & Colitis Foundation
Interventions
OTHEROnline decision aid called IBD&me
Patients randomized to IBD&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
OTHERStandardized educational material
Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
Sponsors
Cedars-Sinai Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Investigator)
Masking description
Given the study design and intervention, it is not possible to ensure the blinding of patients and physicians. However, we will attempt to address the limitations resulting from a lack of blinding: * Patients and the physicians will be informed of the study protocol, but will not be provided accurate information about the specific primary outcome (i.e. comparison between IBD&me and the Crohn's & Colitis Foundation of America (CCFA) resource). The informed consent document will keep participants blind to the study goals. * Physicians will be kept blinded of the patient's assignment group until the clinic visit. * Data will be collected by an independent researcher. Study investigators and the data analyst will remain blinded until all follow-up data is obtained and the primary analysis is finalized.
Intervention model description
Parallel Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age or older * Have ulcerative colitis (UC), Crohn's disease (CD), indeterminate colitis, or inflammatory bowel disease unclassified (IBD-U) * Have experienced IBD related symptoms in the 30 days before screening * Considering discussing biologic therapies for controlling his or her IBD at the next clinic visit * Have an IBD-related visit scheduled at least 7 days and no later than 3 months following screening
Exclusion criteria
* Does not speak English * Does not have access to the Internet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient perceptions of shared decision-making | one day after the clinic visit | To assess the impact of the IBD&me decision aid on patient perceptions of shared decision-making, compared to a standardized education arm. Patient perception of shared decision-making, as measured by the 9-item Shared Decision-Making Questionnaire (SDM-Q-9) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient perceptions of decisional conflict | one day after the clinic visit | Patient perceptions of decisional conflict, as measured using the informed and values clarity subscales of the Decisional Conflict Scale |
| Patient satisfaction | one day after the clinic visit | Patient satisfaction as measured by four domains of the Patient Satisfaction Questionnaire relating to communication, general satisfaction, interpersonal manner, and time spent with the doctor (PSQ-18) |
| Disease control and IBD-related quality of life | at baseline and two months after the clinic visit | Disease control and IBD-related quality of life, as measured by the IBD-Control questionnaire |
| Initiation or switch of a treatment | at baseline and two months after the clinic visit | Questionnaire about IBD therapy use |
Countries
United States
Outcome results
None listed